BioDelivery Sciences International Stock Price Up 7.4% on Analyst Upgrade (BDSI)
BioDelivery Sciences International (NASDAQ:BDSI) shares were up 7.4% on Wednesday after Ladenburg Thalmann raised their price target on the stock to $21.00, StockRatingsNetwork.com reports. Ladenburg Thalmann currently has a buy rating on the stock. BioDelivery Sciences International traded as high as $13.88 and last traded at $13.80, with a volume of 1,142,887 shares. The stock had previously closed at $12.85.
BDSI has been the subject of a number of other recent research reports. Analysts at Roth Capital raised their price target on shares of BioDelivery Sciences International from $15.50 to $16.50 in a research note on Monday. Finally, analysts at Laidlaw reiterated a “buy” rating on shares of BioDelivery Sciences International in a research note on Monday, June 9th. They now have a $15.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $19.92.
The stock’s 50-day moving average is $10.9 and its 200-day moving average is $8.76. The company’s market cap is $672.9 million.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Friday, May 9th. The company reported ($0.11) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.15) by $0.04. The company had revenue of $20.69 million for the quarter, compared to the consensus estimate of $11.60 million. On average, analysts predict that BioDelivery Sciences International will post $-0.65 earnings per share for the current fiscal year.
BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.